Vifor Pharma has pledged to pay £23 million to the NHS after Britain’s competition watchdog raised concerns the drugs firm had been making misleading claims about the safety of a rival’s iron deficiency treatment.
The Competition and Markets Authority (CMA) has been investigating whether Vifor – which makes intravenous iron treatment Ferinject – had spread misinformation to doctors and nurses over Pharmacosmos’s Monofer.
